EyeWorld

Harrow announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar referencing Lucentis (ranibizumab, Genentech) and developed by Samsung Bioepis Co. Ltd. The launch follows Harrow’s announcement last year of its exclusive U.S. commercialization agreement with Samsung Bioepis. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEA (aflibercept, Regeneron).

by Vikram A. Shankar, MD, MPH Ophthalmology continues to strive to balance the goal of environmental sustainability with patient safety concerns. However, mandates surrounding the reuse of ophthalmic medications and instruments are often not supported by robust, standardized evidence and can carry unintended consequences, including increased waste, rising drug costs, medication shortages, and instrument degradation.

by Ellen Stodola Editorial Co-Director Asymposium hosted by the combined societies of the American Society of Cataract and Refractive Surgery (ASCRS), the European Society of Cataract and Refractive Surgeons (ESCRS), and the Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) focused on topics in AI, robotics, and surgical simulation, with representatives from all three societies presenting. Kevin M. Miller, MD, Pannet Pangputhipong, MD, and H.

by Liz Hillman Editorial Co-Director Performing the first FDA-approved WaveLight Plus surgery in the U.S. at OVO LASIK + LENS Source: Mark Lobanoff, MD If refractive surgeons—and the industry that supports them—had a motto, it probably would be to never settle. Just look at the evolution of LASIK treatment planning ecosystems and treatment refinements—traditional, wavefront-guided, wavefront-optimized, topography-guided, and ray tracing.

by Ellen Stodola Editorial Co-Director Corneal tissue procedures are one of the approaches available to help treat corneal conditions, like keratoconus, and offer some patients an option other than transplantation. Several experts discussed these procedures, how they fit in with other options, and how they’re being utilized today. For keratoconus, there were no good treatments for a long time, said Jack Parker, MD, PhD, but in the past 10 years, there have been some new developments.

by Manjool Shah, MD Glaucoma Editor As we find ourselves navigating an era increasingly defined by big data, artificial intelligence, and new digital tools, we are watching our subspecialty transform from a reactive discipline to a highly proactive one. In this issue, we dive into the overarching theme of expanding digital technologies, while also continuing our exploration of nuanced clinical challenges that require our steadfast, long-term vigilance.

by Liz Hillman Editorial Co-Director In the past, this section of EyeWorld has delved into nuanced glaucoma subtypes. In this issue, Won Kim, MD, and Maria Charria, MD, get into the specifics related to traumatic glaucoma. There are many scenarios that can result in traumatic glaucoma. Blunt trauma, Dr. Kim said, can cause hyphema, which increases the likelihood of traumatic glaucoma, with the blood itself clogging the trabecular meshwork. “The more blood, the more risk.

by Harold Dorsey, MD, Ayush Parikh, MD, Gavin Li, MD, Mass Eye and Ear Ophthalmology Residents, Jennifer Lindsey, MD, MBA, Residency Program Director Jennifer Lindsey, MD, MBA Ophthalmology Residency Program Director Mass Eye and Ear Jennifer Lindsey, MD, MBA Ophthalmology Residency Program Director Mass Eye and Ear Jennifer Lindsey, MD, MBA Ophthalmology Residency Program Director Mass Eye and Ear Cataract is the most common reversible cause of vision impairment in the U.S. and accounts for...

The ASCRS Foundation hosted a number of events and sessions at the 2026 ASCRS Annual Meeting in Washington, D.C. In addition to recognizing its 2026 award and grant winners, the ASCRS Foundation hosted a symposium, which focused on domestic volunteerism and Operation Sight. The Party for a Purpose was a huge success, raising funds to benefit Operation Sight. The ASCRS Foundation also hosted several events to recognize and thank both individual and industry donors.

by Susanne Hewitt, MD ASCRS Government Relations Committee Chair ASCRS Government Relations hosted many activities at the ASCRS Annual Meeting in Washington, D.C., in April. This was a great way for staff and Committee members to interact with and share with physicians, industry, and other attendees the value and importance that ASCRS Government Relations brings to the table.